AI-Powered Precision for Medical Practice
Pathway Medical, a Montreal-based company, specializes in AI-powered, evidence-based clinical reference tools. Its team, composed of half physicians, has spent over seven years building one of the largest structured medical databases. This database encompasses nearly all relevant clinical guidelines, medications, and landmark clinical trials across all major medical specialties. Designed specifically for artificial intelligence applications, the database forms the foundation of Pathway's success. Notably, the company's AI model recently achieved a record score of 96 percent on the U.S. Medical Licensing Examination (USMLE), outperforming other models in clinical accuracy.
The acquisition is expected to broaden the reach of these sophisticated tools, offering free access to millions of physicians. Pathway already boasts hundreds of thousands of registered users, with thousands subscribing to its premium paid product. By integrating into the Doximity platform, which reaches over 80 percent of U.S. physicians, Pathway aims to embed its technology directly into clinicians' workflows. Jon Hershon, CEO of Pathway, emphasized that this partnership will enable the delivery of "trusted, evidence-based clinical support directly into the tools that physicians are already using at the point of care".
Strategic Importance for Doximity
Doximity, founded in 2010 and often called "LinkedIn for doctors," offers a platform for medical professionals that includes features such as news feeds, administrative software, telemedicine, and career planning. The acquisition of Pathway complements existing AI tools like Doximity GPT, which already helps doctors create insurance letters and summarize patient records. Pathway's extensive database, linking dosages, guidelines, and scientific literature, will enhance Doximity's ability to provide accurate and rapid answers to clinical questions. Jeff Tangney, co-founder and CEO of Doximity, emphasized, "Pathway has built one of the best medical databases, which will take our clinical reference capabilities to a whole new level."
Market Development and Reactions
The acquisition comes at a time of strong growth for Doximity. Following its IPO in 2021, the company's stock price rose 90 percent in 2024, and it saw another increase of about 8 percent in 2025, reaching a market capitalization of around $11 billion. The integration of Pathway's technology is already being tested, with thousands of doctors using the combined product. Industry experts view the acquisition as a strategic move to meet the growing demand for AI-powered, evidence-based clinical tools that help doctors make informed decisions faster and improve patient care.
Background and Outlook
The acquisition of Pathway is not Doximity's first foray into artificial intelligence. In 2022, the company acquired Amion, a doctor scheduling platform, to expand its portfolio. The current move underscores Doximity's strategic direction to make its platform an indispensable tool for medical professionals, especially at a time when the flood of information in healthcare complicates daily work. At the same time, the company faces legal challenges: a competing company, OpenEvidence, has filed a lawsuit against Doximity and Pathway, accusing them of stealing intellectual property through so-called "prompt injection" attacks. These allegations could influence further development but are disputed by Pathway.
The partnership between Doximity and Pathway is expected to change the way doctors access medical knowledge and could set a new standard for AI-powered clinical decision support.
